2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Simple item page
dc.contributor.authorRoila, F.
dc.contributor.authorMolassiotis, A.
dc.contributor.authorHerrstedt, J.
dc.contributor.authorAapro, M.
dc.contributor.authorGralla, R.
dc.contributor.authorBruera, E.
dc.contributor.authorClark-Snow, R.
dc.contributor.authorDupuis, L.
dc.contributor.authorEinhorn, L.
dc.contributor.authorFeyer, P.
dc.contributor.authorHesketh, P.
dc.contributor.authorJordan, K.
dc.contributor.authorOlver, I.
dc.contributor.authorRapoport, B.
dc.contributor.authorRoscoe, J.
dc.contributor.authorRuhlmann, C.
dc.contributor.authorWalsh, D.
dc.contributor.authorWarr, D.
dc.contributor.authorvan der Wetering, M.
dc.contributor.authoron, B.O.T.P.O.T.M.C.C.C.
dc.date.issued2016
dc.description.abstractDespite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In the late 1990s, several professional organisations published recommendations on the optimal antiemetic prophylaxis in patients submitted to chemotherapy and/or radiotherapy. The European Society of Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) published the results of the third Consensus Conference on antiemetics held in Perugia in June 2009 in Annals of Oncology in 2010 [1]. An update of these recommendations, including studies published from 1 January 2009 to 30 June 2015, was discussed in Copenhagen in June 2015 and is presented in this paper. The methodology for the guideline process is described in detail in the 2010 publication [1]. To change a 2010 recommendation or for a new guideline recommendation to be accepted, a consensus of at least 67% of the expert panellists was needed. As a general rule, the panel considered changes of 10% or greater to be sufficient to warrant the changing of a recommendation.
dc.description.statementofresponsibilityF. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R. J. Gralla, E. Bruera, R. A. Clark-Snow, L. L. Dupuis, L. H. Einhorn, P. Feyer, P. J. Hesketh, K. Jordan I. Olver, B. L. Rapoport, J. Roscoe, C. H. Ruhlmann, D. Walsh, D. Warr, M. van der Wetering on behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen 2015
dc.identifier.citationAnnals of Oncology, 2016; 27(suppl. 5):v119-v133
dc.identifier.doi10.1093/annonc/mdw270
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.orcidOlver, I. [0000-0001-5478-1576]
dc.identifier.urihttp://hdl.handle.net/2440/106572
dc.language.isoen
dc.publisherOxford University Press
dc.rightsCopyright © 2017 European Society for Medical Oncology
dc.source.urihttps://doi.org/10.1093/annonc/mdw270
dc.subjectparticipants of the MASCC/ESMO Consensus Conference Copenhagen 2015
dc.title2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications